Monogenic very-early-onset inflammatory bowel disease due to IL10RA deficiency

For IL10RA c.501T>G (p.Tyr167Ter), a pathogenic nonsense variant that abolishes IL-10 receptor alpha chain expression and causes very early onset inflammatory bowel disease (VEO-IBD) presenting in the first year of life, anti-TNF-alpha monoclonal antibodies (infliximab, adalimumab) serve as the primary pharmacological bridge therapy to control intestinal inflammation before definitive treatment with allogeneic HSCT. IL10RA deficiency disrupts anti-inflammatory IL-10 signaling in macrophages and dendritic cells, leading to uncontrolled TNF-alpha and IL-1beta-driven colitis. Anti-TNF antibodies directly neutralize this downstream effector cytokine. While antibody therapy does not address the root genetic cause, it is essential for disease stabilization, nutritional optimization, and surgical avoidance prior to transplant.

Glocker et al. (2009, PMID: 19890111, NEJM) first identified IL10/IL10R deficiency as a monogenic cause of VEO-IBD, establishing that loss of IL-10 signaling leads to severe infantile colitis unresponsive to conventional immunosuppression. Clinical case series have reported partial response to infliximab (chimeric anti-TNF IgG1) in IL10RA-deficient patients, with reduction in bloody diarrhea and inflammatory markers, though responses are often incomplete and temporary compared to typical pediatric IBD. Kotlarz et al. (2012, PMID: 23000145) reported that HSCT is the only curative approach, with successful immune reconstitution and IBD resolution in transplanted patients. Anti-TNF therapy has been used in >50 reported IL10RA-deficient patients as a pre-transplant bridge, with variable efficacy. For p.Tyr167Ter, the complete absence of IL10RA surface expression (confirmed by flow cytometry) predicts absent STAT3 phosphorylation in response to IL-10, complete loss of anti-inflammatory feedback, and typically severe refractory colitis requiring early HSCT.

Anti-TNF antibodies provide symptomatic relief but do not cure IL10RA deficiency — they address one downstream effector (TNF-alpha) while the broader IL-10 signaling defect persists. Many IL10RA-deficient patients are partially or completely refractory to anti-TNF therapy, likely because inflammation is driven by multiple cytokines beyond TNF. Infliximab carries risks of serious infection (particularly relevant in immunodeficient infants), infusion reactions, and anti-drug antibody formation leading to loss of response. The definitive treatment remains allogeneic HSCT, which has significant transplant-related mortality (estimated 10-20% in VEO-IBD cohorts) and graft-versus-host disease risk. For p.Tyr167Ter, the very early presentation (typically first weeks to months of life) means that anti-TNF therapy must be initiated in young infants, raising pharmacokinetic and safety concerns in this age group. Gene therapy for IL10RA deficiency (ex vivo HSPC correction) is theoretically possible but has not been developed, partly because HSCT outcomes are generally favorable when performed early.

For IL10RA c.506T>C (p.Ile169Thr), a pathogenic missense variant that disrupts IL-10 receptor signaling and causes severe very-early-onset inflammatory bowel disease (VEOIBD), monoclonal antibody therapy with anti-TNFα agents (infliximab, adalimumab) and anti-IL-12/23 antibodies (ustekinumab) can provide critical disease control as a bridge to definitive curative allogeneic HSCT. While antibody therapy does not correct the underlying genetic defect, it targets the downstream inflammatory cascade driven by unopposed macrophage and T cell activation in the absence of functional IL-10 signaling.

IL-10 is a master anti-inflammatory cytokine; its receptor (IL-10RA/IL-10RB heterodimer) signals through JAK1/TYK2-STAT3 to suppress macrophage and dendritic cell proinflammatory cytokine production (TNFα, IL-1β, IL-6, IL-12, IL-23). Biallelic IL10RA loss-of-function variants cause severe colitis presenting in the first months of life, refractory to conventional immunosuppression. The p.Ile169Thr substitution affects the extracellular domain of IL-10RA, likely disrupting IL-10 ligand binding or receptor conformational signaling. Multiple case series have reported partial clinical response to infliximab (anti-TNFα) in IL10RA-deficient VEOIBD, with reduction in bloody diarrhea, fistulae, and inflammatory markers (Glocker et al., NEJM 2009; PMID:19890111; Kotlarz et al., Gastroenterology 2012; PMID:22902955). Ustekinumab (anti-IL-12/23 p40 subunit) has been used in refractory cases, targeting the Th1/Th17 axis that is overactivated when IL-10 suppression fails. However, long-term remission requires HSCT to replace the defective hematopoietic cells with donor-derived immune cells expressing functional IL-10RA.

Antibody therapy is palliative, not curative — it does not restore IL-10 signaling. Responses are often partial and wane over time, with frequent need for dose escalation or switching agents. Anti-TNFα therapy carries risks of serious infections (opportunistic infections, tuberculosis reactivation) particularly concerning in infants who are already immunocompromised by their primary immunodeficiency. Immunogenicity (anti-drug antibody formation) limits long-term efficacy of infliximab and adalimumab. The definitive treatment is allogeneic HSCT, which has shown high cure rates (~80-90% event-free survival) when performed early, but carries its own transplant-related mortality and morbidity. Antibody therapy data for IL10RA-VEOIBD come from small case series and case reports — no randomized controlled trials exist for this ultra-rare condition. The specific effect of the p.Ile169Thr variant on antibody therapy response has not been studied.

For IL10RA c.349C>T (p.Arg117Cys), a pathogenic missense variant in the extracellular domain of the IL-10 receptor alpha chain that impairs IL-10 signaling and causes very-early-onset inflammatory bowel disease (VEO-IBD), anti-cytokine antibody therapy (infliximab/anti-TNF-alpha, ustekinumab/anti-IL-12/23) serves a critical role as bridge therapy to control intestinal inflammation before definitive curative treatment with allogeneic HSCT. While antibody therapy does not correct the underlying IL-10 signaling defect, it targets the downstream pro-inflammatory cascade (TNF-alpha, IL-12/23 axis) that drives tissue destruction when the IL-10 anti-inflammatory feedback loop is broken. Disease control with biological agents can improve nutritional status, reduce surgical complications, and optimize the patient for transplant conditioning.

Multiple case series have demonstrated that anti-TNF therapy (infliximab, adalimumab) achieves partial or complete endoscopic and clinical remission in a subset of IL10RA-deficient VEO-IBD patients (Kotlarz et al., Gastroenterology 2012; PMID:22504044; Engelhardt et al., J Allergy Clin Immunol 2013; PMID:23791516). The mechanistic rationale is that loss of IL-10 signaling removes the negative feedback on macrophage and dendritic cell pro-inflammatory cytokine production, leading to excessive TNF-alpha and IL-12/23-driven intestinal inflammation. Anti-TNF antibodies directly neutralize this excess TNF. For p.Arg117Cys, Arg117 is located in the extracellular ligand-binding domain of IL10RA and likely participates in IL-10 binding through electrostatic interactions; the cysteine substitution disrupts this contact and may also create aberrant disulfide bonds affecting receptor dimerization. ClinVar classifies this variant as Pathogenic. HSCT is the definitive curative therapy, with reported cure rates of >80% in experienced centers (Moens et al., J Clin Immunol 2023), by replacing the defective hematopoietic compartment with donor-derived immune cells capable of normal IL-10 signaling.

Anti-TNF and anti-IL-12/23 antibodies do not address the primary defect (IL-10 receptor dysfunction) and achieve only partial disease control in most IL10RA-deficient patients — complete sustained remission without HSCT is rare. Many patients become refractory to biological therapy over time, and some require colectomy for refractory colitis before transplant can be arranged. The infantile presentation (typically <2 years) means that anti-cytokine antibodies are used off-label in an extremely young patient population with limited pharmacokinetic data. Immunosuppression from anti-TNF therapy in the context of an already-dysregulated immune system (impaired IL-10-mediated immunoregulation) increases infection risk, particularly relevant in malnourished infants. The bridge-to-HSCT strategy requires timely donor identification and transplant center access, which may not be available in all settings. For p.Arg117Cys specifically, if the variant results in partially functional IL10RA with reduced (rather than absent) IL-10 signaling, the VEO-IBD phenotype may be milder and more responsive to biological therapy, potentially delaying the need for HSCT in select patients — but this requires formal functional characterization of each variant to guide management.

Base Editing (BE4max) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Monogenic very-early-onset inflammatory bowel disease due to IL10RA deficiency targeting the IL10RA c.506T>C (p.Ile169Thr) variant (Pathogenic, missense variant, non-coding transcript variant). The editing system (BE4max (cytosine base editor)) converts the pathogenic C to T (or G to A on the target strand), restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct biallelic loss-of-function variants in IL10RA at the intestinal immune-cell and epithelial-cell loci to restore IL-10 signalling and achieve permanent remission of very-early-onset inflammator. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: IL10RA NM_001558.4(IL10RA):c.506T>C (p.Ile169Thr) is classified as Pathogenic (ClinVar variation ID 943905). Molecular consequence: missense variant, non-coding transcript variant. Protein change: I169T. 2. Epidemiology: IL10RA-deficient very-early-onset IBD is an ultra-rare autosomal recessive monogenic form of inflammatory bowel disease, typically presenting in the first months of life with severe enterocolitis, perianal disease, and failure to thrive. Cohort and regional data suggest that monogenic VEO-IBD consti 3. Standard of care: Conventional IBD therapies (steroids, immunomodulators, biologics such as anti-TNF or vedolizumab) rarely induce sustained remission in IL10RA-deficient VEO-IBD; most patients remain dependent on parenteral nutrition, have persistent disease activity, and often require surgery. Multiple cohort studi 4. Pipeline: For IL10RA/B monogenic IBD, there are currently no registered in vivo gene therapy or gene-editing clinical trials identified in public registries; HSCT is used as a standard curative cellular therapy in specialized centers. Gene therapy and gene editing for intestinal and immune targets are at prec 5. CBE clinical validation: BE4max (Koblan et al. 2018) is the gold-standard cytosine base editor. Multiple CBE programs are in clinical development for liver and hematologic targets.

1. No published data specifically correcting IL10RA c.506T>C (p.Ile169Thr) with Base Editing (BE4max); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.